The clinical value of combined assessment of inflammatory biomarkers and liver reserve function in predicting the 12-week prognosis of HBV-ACLF
Immunobiology · 2026
DOI: 10.1016/j.imbio.2025.153147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunobiology, 2026. Verfasst von Ke Luo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Disease, Meizhou People's Hospital (Meizhou Academy of Medical Sciences), Meizhou 514031, Guangdong, China. Electronic address: l…. Hauptthemen laut MEDLINE: Biomarkers, Acute-On-Chronic Liver Failure, Liver, Hepatitis B virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND: Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) represents a serious clinical condition characterized by acute deterioration of liver function in patients with chronic liver disease. Prompt and precise prognostic assessment is key to guiding therapy and improving clinical outcomes. OBJECTIVE: To investigate the clinical value of combined assessment of inflammatory biomarkers and liver reserve function indicators in predicting the 12-week prognosis of patients with HBV-ACLF. METHODS: We analyzed clinical data from 150 HBV-ACLF patients admitted between July 2022 and December 2024. Patients were followed for 12 weeks and categorized into survival or death groups. Baseline data included inflammatory biomarkers [Neutrophil count (NEUT), Lymphocyte count (LYM), Monocyte count (MON), Platelet count (PLT), Procalcitonin (PCT)] and liver function indicators [Albumin (ALB), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Total bilirubin (TBIL), International normalized ratio (INR)]. Pearson correlation analysis was performed for statistically significant indicators. The construction of the combined prediction model for 12-week prognosis of HBV-ACLF was performed using multivariate logistic regression analysis. The application value of combining inflammatory biomarkers with liver reserve function indicators in the 12-week prognostic assessment of HBV-ACLF was evaluated using ROC curve analysis. P-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Liver Disease, Meizhou People's Hospital (Meizhou Academy of Medical Sciences), Meizhou 514031, Guangdong, China. Electronic address: luoke11930@hotmail.com.
- Department of Liver Disease, Meizhou People's Hospital (Meizhou Academy of Medical Sciences), Meizhou 514031, Guangdong, China.
Zitieren
APA
Luo, K., & Liu, T. (2026). The clinical value of combined assessment of inflammatory biomarkers and liver reserve function in predicting the 12-week prognosis of HBV-ACLF. Immunobiology. https://doi.org/10.1016/j.imbio.2025.153147
Vancouver
Luo K, Liu T. The clinical value of combined assessment of inflammatory biomarkers and liver reserve function in predicting the 12-week prognosis of HBV-ACLF. Immunobiology. 2026. doi:10.1016/j.imbio.2025.153147
BibTeX
@article{Luo2026,
author = {Luo, Ke and Liu, Tianhuang},
title = {The clinical value of combined assessment of inflammatory biomarkers and liver reserve function in predicting the 12-week prognosis of HBV-ACLF},
journal = {Immunobiology},
year = {2026},
doi = {10.1016/j.imbio.2025.153147}
}
EUVIMED